CrackitToday App

WHO has added GLP-1 receptor agonists to its Model List of Essential Medicines (EML) for type-2 diabetes

Kumari Sonali

WHO has added GLP-1 receptor agonists to its Model List of Essential Medicines (EML) for type-2 diabetes:

The WHO has added GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, tirzepatide) to its Model List of Essential Medicines (EML) for type-2 diabetes with comorbidities like obesity and cardiovascular/kidney disease.Glucagon-Like Peptide-1 (GLP-1) drugs are medications that mimic the action of the natural GLP-1 hormone. They belong to the class of GLP-1 receptor agonists (also called incretin mimetics). Aimis to  Lower blood glucose in type-2 diabetes patients, to Support weight loss, improve cardio-metabolic health, and reduce diabetes complications (heart/kidney).

 

...Read more on our test console

...Read these too

  • GLP-1 receptor agonists

    GLP-1 receptor agonists: The WHO has endorsed GLP-1 receptor agonists, a new class of drugs for managing obesity, marking a shift in global health strategies to combat the growing obesity…

  • Type-1 Diabetes

    Type-1 Diabetes: In June 2022, the Indian Council of Medical Research (IMCR) released guidelines for the diagnosis, treatment, and management for type-1 diabetes. This is the first time the ICMR…

  • Type 5 Diabetes : Recognized

    Type 5 Diabetes : Recognized Type 5 diabetes has been officially recognised as a distinct form of diabetes by the International Diabetes Federation. Type 5 diabetes primarily affects lean, undernourished…